{
    "id": "34b4a9e3-da8a-a31c-e063-6394a90add1d",
    "indications": {
        "text": "guanfacine extended-release tablets indicated treatment attention deficit hyperactivity disorder ( adhd ) monotherapy adjunctive therapy stimulant medications [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "attention deficit hyperactivity disorder (DOID:1094)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1094"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "recommended dose : 1 mg 7 mg ( 0.05-0.12 mg/kg target weight based dose range ) daily morning evening based response tolerability ( 2.2 ) . begin dose 1 mg daily adjust increments 1 mg/week ( 2.2 ) . crush , chew break tablets swallowing ( 2.1 ) . administer high-fat meals , increased exposure ( 2.1 ) . substitute immediate-release guanfacine tablets mg-per-mg basis , differing pharmacokinetic profiles ( 2.3 ) . switching immediate-release guanfacine , discontinue treatment titrate guanfacine extended-release tablets directed ( 2.3 ) . discontinuing , taper dose decrements 1 mg every 3 7 days avoid rebound hypertension ( 2.5 ) .",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "guanfacine extended-release tablets , usp supplied 2 mg strength extended-release tablets color : white , shape : caplet , debossment ( top/bottom ) : a534/ 2 mg ndc : 70518-3809-00 packaging : 30 1 blister pack storage - store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "guanfacine extended-release tablets contraindicated patients history hypersensitivity reaction guanfacine extended-release tablets inactive ingredients , products containing guanfacine . rash pruritus reported .",
    "ingredients": [
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "POLYVINYL ACETATE",
            "code": "32K497ZK2U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30089"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11061"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "GUANFACINE",
            "code": "30OMY4G3MK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5558"
        }
    ],
    "organization": "REMEDYREPACK INC.",
    "name": "Guanfacine",
    "effectiveTime": "20250509",
    "indications_original": "Guanfacine extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [\n \n  see\n                     Clinical Studies (\n                     \n                        14\n                     \n                     )].",
    "contraindications_original": "Recommended dose: 1 mg to 7 mg (0.05-0.12 mg/kg target weight based dose range) once daily in the morning or evening based on clinical response and tolerability ( 2.2 ) . Begin at a dose of 1 mg once daily and adjust in increments of no more than 1 mg/week ( 2.2 ) . Do not crush, chew or break tablets before swallowing ( 2.1 ) . Do not administer with high-fat meals, because of increased exposure ( 2.1 ) . Do not substitute for immediate-release guanfacine tablets on a mg-per-mg basis, because of differing pharmacokinetic profiles ( 2.3 ) . If switching from immediate-release guanfacine, discontinue that treatment and titrate with guanfacine extended-release tablets as directed ( 2.3 ) . When discontinuing, taper the dose in decrements of no more than 1 mg every 3 to 7 days to avoid rebound hypertension ( 2.5 ) .",
    "warningsAndPrecautions_original": "Guanfacine extended-release tablets, USP are supplied in 2 mg strength extended-release tablets in\n                  Color: White, Shape: Caplet, Debossment (top/bottom): A534/ 2 mg\n                  \n                  NDC: 70518-3809-00\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Storage\u00a0- Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [see USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Guanfacine extended-release tablets are contraindicated in patients with a history of a hypersensitivity reaction to guanfacine extended-release tablets or its inactive ingredients, or other products containing guanfacine. Rash and pruritus have been reported.",
    "drug": [
        {
            "name": "Guanfacine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5558"
        }
    ]
}